Hansoh Pharmaceutical Group Company Limited (3692.HK) HKSE

35.78

-0.72(-1.97%)

Updated at October 20 09:43AM

Currency In HKD

Hansoh Pharmaceutical Group Company Limited

Address

No.45 Huanghe Road

Lianyungang, 222069

China

Phone

86 21 3177 3517

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

8989

First IPO Date

June 14, 2019

Key Executives

NameTitlePayYear Born
Ms. Huijuan ZhongChairlady, Chief Executive Officer & President12.92M1961
Dr. Aifeng LyuExecutive Director3.2M1977
Ms. Yuan SunExecutive Director7.93M1987
Mr. Chuanhe XuSenior Vice President01964
Dr. Chih-Hung LeeChief of Science Officer01960
Mr. Min HuVice President & Chief Financial Officer01977
Dr. Shan JiangChief Technology Officer01970
Mr. Weiyong SunChief Business Officer01971
Dr. Xiaoqing ZhangChief Medical Officer01974
Ms. Shengli ZhongJoint Company Secretary & Senior Vice President01968

Description

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.